Lynn Navale

11.6k total citations · 1 hit paper
59 papers, 2.1k citations indexed

About

Lynn Navale is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Lynn Navale has authored 59 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 19 papers in Immunology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Lynn Navale's work include CAR-T cell therapy research (36 papers), Biosimilars and Bioanalytical Methods (14 papers) and Lymphoma Diagnosis and Treatment (13 papers). Lynn Navale is often cited by papers focused on CAR-T cell therapy research (36 papers), Biosimilars and Bioanalytical Methods (14 papers) and Lymphoma Diagnosis and Treatment (13 papers). Lynn Navale collaborates with scholars based in United States, Canada and Belgium. Lynn Navale's co-authors include Sattva S. Neelapu, William Y. Go, Jeff Wiezorek, Michael Crump, Christian Gisselbrecht, John Kuruvilla, Umar Farooq, Sami Boussetta, Annette E. Hay and Jason R. Westin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Lynn Navale

57 papers receiving 2.0k citations

Hit Papers

Outcomes in refractory diffuse large B-cell lymphoma: res... 2017 2026 2020 2023 2017 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
    2017 1.0k citations Michael Crump, Sattva S. Neelapu et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lynn Navale United States 17 1.7k 863 387 317 267 59 2.1k
Annette E. Hay Canada 15 1.0k 0.6× 846 1.0× 262 0.7× 219 0.7× 170 0.6× 82 1.6k
Javier Muñoz United States 23 1.2k 0.7× 886 1.0× 357 0.9× 333 1.1× 170 0.6× 133 1.8k
Paolo F. Caimi United States 23 1.5k 0.9× 948 1.1× 467 1.2× 387 1.2× 134 0.5× 209 2.2k
Timothy S. Fenske United States 27 1.7k 1.0× 1.2k 1.4× 435 1.1× 522 1.6× 160 0.6× 162 2.6k
Anthony R. Mato United States 24 1.9k 1.2× 1.1k 1.2× 632 1.6× 619 2.0× 323 1.2× 85 2.8k
Özlem Anak Switzerland 12 1.6k 1.0× 305 0.4× 521 1.3× 341 1.1× 286 1.1× 25 2.0k
Alex F. Herrera United States 28 2.5k 1.5× 2.1k 2.4× 392 1.0× 642 2.0× 210 0.8× 239 3.5k
Amitkumar Mehta United States 20 834 0.5× 515 0.6× 240 0.6× 349 1.1× 66 0.2× 114 1.3k
Carla Casulo United States 19 1.1k 0.7× 1.3k 1.5× 244 0.6× 400 1.3× 46 0.2× 95 1.9k
Kim Linton United Kingdom 24 1.1k 0.6× 1.2k 1.3× 421 1.1× 289 0.9× 44 0.2× 122 2.2k

Countries citing papers authored by Lynn Navale

Since Specialization
Citations

This map shows the geographic impact of Lynn Navale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn Navale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn Navale more than expected).

Fields of papers citing papers by Lynn Navale

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn Navale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn Navale. The network helps show where Lynn Navale may publish in the future.

Co-authorship network of co-authors of Lynn Navale

This figure shows the co-authorship network connecting the top 25 collaborators of Lynn Navale. A scholar is included among the top collaborators of Lynn Navale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn Navale. Lynn Navale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Locke, Frederick L., Javier Muñoz, Michael Tees, et al.. (2025). Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. Journal of Clinical Oncology. 43(14). 1695–1705. 11 indexed citations
2.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2021). Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances. 5(20). 4149–4155. 45 indexed citations
3.
Oluwole, Olalekan O., Jeroen P. Jansen, Vincent Lin, et al.. (2020). Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation. 26(9). 1581–1588. 41 indexed citations
4.
5.
Oluwole, Olalekan O., Jeroen P. Jansen, Victor S. Lin, et al.. (2019). PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL). Value in Health. 22. S522–S522. 2 indexed citations
6.
Bansal, Aasthaa, Sean D. Sullivan, Vincent Lin, et al.. (2019). Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models. Medical Decision Making. 39(3). 294–298. 19 indexed citations
7.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2019). A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. Blood. 134(Supplement_1). 4095–4095. 7 indexed citations
8.
Crump, Michael, Sattva S. Neelapu, Umar Farooq, et al.. (2017). Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 130(16). 1800–1808. 1042 indexed citations breakdown →
9.
10.
Locke, Frederick L., Jason R. Westin, David B. Miklos, et al.. (2017). Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 35(15_suppl). TPS7572–TPS7572. 9 indexed citations
11.
Neelapu, Sattva S., John M. Rossi, Frederick L. Locke, et al.. (2017). PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI‐CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI‐CEL). Hematological Oncology. 35(S2). 262–263. 2 indexed citations
12.
13.
Neelapu, Sattva S., Frederick L. Locke, Nancy L. Bartlett, et al.. (2016). ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Annals of Oncology. 27. vi325–vi325. 2 indexed citations
14.
Wang, M., Frederick L. Locke, Tanya Siddiqi, et al.. (2016). ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL). Annals of Oncology. 27. vi326–vi326. 7 indexed citations
15.
16.
Wayne, Alan S., Leonard S. Sender, Rupert Handgretinger, et al.. (2016). ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. Journal of Clinical Oncology. 34(15_suppl). TPS7075–TPS7075. 5 indexed citations
17.
Perez, Arianne, Lynn Navale, John M. Rossi, et al.. (2015). Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy. Blood. 126(23). 2042–2042. 3 indexed citations
18.
Lü, Jianfeng, Erik Rasmussen, Beth Y. Karlan, et al.. (2011). Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemotherapy and Pharmacology. 69(5). 1135–1144. 34 indexed citations
19.
Hecht, J. Randolph, Amita Patnaik, Jordan Berlin, et al.. (2007). Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 110(5). 980–988. 158 indexed citations
20.
Peeters, Marc, Eric Van Cutsem, Jordan Berlin, et al.. (2007). Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials. Journal of Clinical Oncology. 25(18_suppl). 4138–4138. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annette E. Hay Breakdown of academic impact, for papers by Javier Muñoz Breakdown of academic impact, for papers by Paolo F. Caimi Breakdown of academic impact, for papers by Timothy S. Fenske Breakdown of academic impact, for papers by Anthony R. Mato Breakdown of academic impact, for papers by Özlem Anak Breakdown of academic impact, for papers by Alex F. Herrera Breakdown of academic impact, for papers by Amitkumar Mehta Breakdown of academic impact, for papers by Carla Casulo Breakdown of academic impact, for papers by Kim Linton
Rankless by CCL
2026